Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…
Akcea Therapeutics Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…
Dova Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…
Mersana Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…
Evolent Health, Inc. Common Stock Secondary Offering
Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 4,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of…
Back to top